TM Bioscience shareholders and optionholders approve proposed acquisition by Luminex Corporation
Tm Bioscience Corporation announced that Tm Bioscience shareholders and optionholders have approved the acquisition of Tm Bioscience by Luminex Corporation at the Company's Special Meeting of shareholders and optionholders. Shareholders and optionholders representing more than 98 percent of all votes cast voted in favour of the transaction.
The approved merger will be submitted to the Ontario Superior Court of Justice for final court approval on or about February 27, 2007. If court approval is obtained and other customary conditions to closing are satisfied the transaction is expected to close on or about February 28, 2007, at which time all Tm Bioscience shareholders will be entitled to receive 0.06 Luminex common shares in exchange for each Tm Bioscience common share.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Hookworm
Vipera_monticola

New insights into the evolution of the plague pathogen - A research team from Kiel University and MPI-EB identifies genetic factors that were acquired by the pathogen Yersinia pestis during its recent evolution
Joan_A._Steitz
The_Michael_J._Fox_Foundation
G._H._Hardy

Autoimmune disorders and regulatory B cells – marker identified

Predicting cancer risk more precisely - Li-Fraumeni syndrome: A new type of cluster analysis makes customised cancer screening tests possible
